As popular as peptide therapies have become in oncology and metabolic research, a new industry report suggests their next frontier may be in conjugate platforms. According to SNS Insider, the global peptide drug conjugates (PDC) market is projected to grow from USD 3.85 billion in 2025 to USD 15.05 billion by 2035, marking a compound annual growth rate of 14.6%.
Peptide drug conjugates are designed to deliver toxic, radioactive, or bioactive payloads directly to diseased cells by attaching them to short “homing” peptides. Unlike antibody‑drug conjugates, peptides are cheaper to synthesize, penetrate tumors more effectively, and carry lower immunogenic risk. Analysts say this makes them a promising alternative in precision medicine, particularly as oncology demand continues to rise.
Oncology Leads, But Other Fields Emerging
The report notes that oncology accounts for nearly 77% of current PDC revenues, with radiopharmaceutical conjugates targeting PSMA and somatostatin receptors anchoring commercial success.
Cytotoxic and antigen‑independent platforms are advancing into trials for difficult cancers, showing that PDCs can deliver efficacy even without receptor overexpression. At the same time, pipelines are diversifying into immunology, autoimmune diseases, metabolic disorders, and infectious diseases, signaling broader applications beyond cancer.
Regional Outlook
North America remains the largest market, projected to reach USD 5.81 billion by 2035, supported by Novartis’s radioligand platform and a mature reimbursement ecosystem. Europe is expected to grow to USD 3.72 billion, driven by Germany’s production capacity and the UK’s innovation in bicyclic peptide conjugates. Asia‑Pacific is forecast to be the fastest‑growing region, with a 17.8% CAGR, fueled by Japan’s peptide macrocycle expertise and China’s expanding contract manufacturing capabilities.
Despite optimism, hurdles remain. PDCs face metabolic instability and linker degradation, issues highlighted by the withdrawal of Pepaxto after post‑marketing safety concerns.
The Bigger Picture
For peptide researchers and companies, the forecast underscores how conjugate platforms are moving from niche oncology applications into mainstream precision medicine. Analysts say the next decade will determine whether PDCs can expand beyond cancer into chronic diseases, potentially reshaping the peptide therapy landscape.
Related Coverage: As GLP‑1 peptide drugs reshape obesity treatment worldwide, Brazil’s public health system is fighting over whether to provide them free through SUS. See our coverage of Brazil’s GLP‑1 Access Battle.